ZYXI - Zynex, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
3.1000
-0.0500 (-1.59%)
As of 12:56PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close3.1500
Open3.1000
Bid0.00 x 0
Ask0.00 x 0
Day's Range3.1000 - 3.1100
52 Week Range2.4000 - 5.5000
Volume1,049
Avg. Volume16,638
Market Cap100.412M
Beta (3Y Monthly)1.15
PE Ratio (TTM)10.40
EPS (TTM)0.30
Earnings DateNov 12, 2018 - Nov 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2018-12-31
1y Target Est6.92
Trade prices are not sourced from all markets
  • ACCESSWIRE21 days ago

    Zynex to Present at the 11th Annual LD Micro Main Event

    LOS ANGELES, CA / ACCESSWIRE / November 20, 2018 / Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced that it will be presenting at the 11th annual LD Micro Main Event on Tuesday, December 4th at 4:30pm PST / 7:30pm EST. Zynex's CEO, Thomas Sandgaard will be presenting and meeting with investors. The LD Micro Main Event will take place December 4th, 5th, and 6th, in Los Angeles at the Luxe Sunset Bel Air Hotel, will feature 250 companies, and will be attended by over 1,200 individuals.

  • Thomson Reuters StreetEvents29 days ago

    Edited Transcript of ZYXI earnings conference call or presentation 6-Nov-18 4:00pm GMT

    Q3 2018 Zynex Inc Earnings Call

  • Zynex Announces 2018 Third Quarter Earnings and Special Dividend
    PR Newswirelast month

    Zynex Announces 2018 Third Quarter Earnings and Special Dividend

    - Revenue increased 19% year over year to $8.1 million - Net income of $2.6 million increased 18% year over year; Diluted EPS $0.08 - Adjusted EBITDA of $3.0 million - Board of Directors declares a one-time ...

  • Zynex Schedules 2018 Third Quarter Earnings Release and Webcast
    PR Newswirelast month

    Zynex Schedules 2018 Third Quarter Earnings Release and Webcast

    ENGLEWOOD, Colo. , Nov. 2, 2018 /PRNewswire/ -- Zynex (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, ...

  • Zynex Obtains U.S. Patent for Blood Volume Monitor
    PR Newswire2 months ago

    Zynex Obtains U.S. Patent for Blood Volume Monitor

    ENGLEWOOD, Colo., Oct. 8, 2018 /PRNewswire/ -- Zynex, Inc. (ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announces that it has obtained a U.S. utility patent for its Blood Volume Monitor Device. Thomas Sandgaard, the inventor, has assigned the patent to Zynex's subsidiary, Zynex Monitoring Solutions.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of ZYXI earnings conference call or presentation 8-May-18 3:00pm GMT

    Q1 2018 Zynex Inc Earnings Call

  • Zynex to Present at the Ladenburg Thalmann 2018 Healthcare Conference
    PR Newswire3 months ago

    Zynex to Present at the Ladenburg Thalmann 2018 Healthcare Conference

    ENGLEWOOD, Colo., Sept. 25, 2018 /PRNewswire/ -- Zynex, Inc. (ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, and neurological diagnostics, today announced that Thomas Sandgaard, Chief Executive Officer of Zynex, will be presenting at the Ladenburg Thalmann 2018 Healthcare Conference, on Tuesday October 2, 2018 at 2:30 pm EDT.  The conference will be held at the Sofitel Hotel in New York City.

  • Zynex to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
    PR Newswire3 months ago

    Zynex to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

    Thomas Sandgaard, Chief Executive Officer of Zynex, will provide an overview of the Company's business in a presentation scheduled on Thursday, September 6, 2018 at 12:05 pm EDT. Management will also be meeting with members of the investment community during one-on-one meetings.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of ZYXI earnings conference call or presentation 2-Aug-18 5:00pm GMT

    Q2 2018 Zynex Inc Earnings Call

  • ACCESSWIRE4 months ago

    SeeThruEquity Issues Update on Zynex, Inc.

    NEW YORK, NY / ACCESSWIRE / August 16, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has ...

  • ACCESSWIRE4 months ago

    Consilium Global Research Issues Quarterly Update on Zynex, Inc (OTCQB: ZYXI)

    ST. PETERSBURG, FL / ACCESSWIRE / August 10, 2018 / Consilium Global Research (CGR) an Investor Recognition Company that connects Companies with Investors, today announced that it has issued an Update ...

  • Zynex Announces 2018 Second Quarter Earnings
    PR Newswire4 months ago

    Zynex Announces 2018 Second Quarter Earnings

    - Revenue increased 50% year over year to $7.6 million - Net income of $2.4 million increased 61% year over year; Diluted EPS $0.07 - Adjusted EBITDA of $2.8 million increased 41% year over year - Eighth ...

  • Zynex Schedules 2018 Second Quarter Earnings Release and Webcast
    PR Newswire5 months ago

    Zynex Schedules 2018 Second Quarter Earnings Release and Webcast

    LONE TREE, Colo. , July 27, 2018 /PRNewswire/ -- Zynex (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, ...

  • Zynex Recognized in Top 100 Public Companies by ColoradoBiz
    PR Newswire7 months ago

    Zynex Recognized in Top 100 Public Companies by ColoradoBiz

    ENGLEWOOD, Colo., May 23, 2018 /PRNewswire/ -- Zynex (ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurodiagnostic equipment, today announced that ColoradoBiz Magazine has recognized Zynex as a Top100 Public Company in its May/June 2018 issue. Zynex was ranked 83rd on 2017 revenue of $23.4 million up from 90th in 2016 on $13.3 million in revenue. For over 45 years, state officials, company executives and business professionals have looked to ColoradoBiz as the statewide voice of our business community.

  • ACCESSWIRE7 months ago

    Consilium Global Research Issues Quarterly Update on Zynex, Inc (OTCQB: ZYXI)

    ST. PETERSBURG, FL / ACCESSWIRE / May 18, 2018 / Consilium Global Research (CGR) an Investor Recognition Company that connects Companies with Investors, today announced that it has issued an Update Report ...

  • ACCESSWIRE7 months ago

    SeeThruEquity Issues Update on Zynex, Inc.

    NEW YORK, NY / ACCESSWIRE / May 15, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Zynex, Inc. (ZYXI). Based in Lone Tree, CO, Zynex, Inc. (ZYXI), "Zynex" produces medical devices that utilize electrotherapy to treat pain and rehabilitation. The company's flagship product, NexWave™, is an FDA-cleared electrotherapy medical device that offers non-invasive, non-addictive treatment of chronic and acute pain.

  • Zynex Announces Share Buyback Program
    PR Newswire7 months ago

    Zynex Announces Share Buyback Program

    ENGLEWOOD, Colo., May 14, 2018 /PRNewswire/ -- Zynex, Inc. (ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced that its board of directors approved a program to buy back an additional $2 million of the Company's common stock.  The new program will commence on May 14, 2018 and is scheduled to terminate on May 13, 2019 or when the $2 million buyback limit is reached. The Company previously re-purchased 495,091 shares of its common stock under a prior buyback program from December 6, 2017 through March 6, 2018. In making the announcement, Zynex President and CEO Thomas Sandgaard stated, "We are committed to delivering shareholder value, and this buyback program authorization reflects the board's confidence in both our short-term prospects and our long term growth strategy.

  • Zynex Announces 2018 First Quarter Earnings
    PR Newswire7 months ago

    Zynex Announces 2018 First Quarter Earnings

    - Revenue grew 100% year over year to $6.9 million - Net income of $1.9 million increased 444% year over year; Diluted EPS $0.06 - Adjusted EBITDA of $2.0 million increased 257% year over year - Seventh ...

  • Zynex Schedules 2018 First Quarter Earnings Release and Webcast
    PR Newswire7 months ago

    Zynex Schedules 2018 First Quarter Earnings Release and Webcast

    LONE TREE, Colo. , May 1, 2018 /PRNewswire/ -- Zynex (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, ...

  • OTCQX And OTCQB Companies to Present At 2018 ROTH Conference
    PR Newswire9 months ago

    OTCQX And OTCQB Companies to Present At 2018 ROTH Conference

    OTC Markets Group EVP Jason Paltrowitz to Speak on Panel on "Reg A+ Offerings" NEW YORK , March 8, 2018 /PRNewswire/ -- OTC Markets Group Inc.  (OTCQX: OTCM), operator of financial markets for ...

  • ACCESSWIRE9 months ago

    Consilium Global Research Issues Quarterly Update on Zynex, Inc (OTCQB: ZYXI)

    ST. PETERSBURG, FL / ACCESSWIRE / March 8, 2018 / Consilium Global Research (CGR) an Investor Recognition Company that connects Companies with Investors, today announced that it has issued an Update Report ...

  • ACCESSWIRE9 months ago

    SeeThruEquity Issues Update on Zynex, Inc.

    NEW YORK, NY / ACCESSWIRE / March 7, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued ...

  • Zynex Appoints New Independent Board Member
    PR Newswire9 months ago

    Zynex Appoints New Independent Board Member

    ENGLEWOOD, Colo., March 6, 2018 /PRNewswire/ -- Zynex, Inc. (ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced the appointment of Joshua R. Disbrow to its Board of Directors and Audit Committee. Mr. Disbrow has been in the life sciences industry for over twenty years across pharmaceuticals, diagnostics, and medical devices. Currently, Mr. Disbrow serves as the Chairman and Chief Executive Officer of Aytu BioScience, Inc. ("Aytu" NASDAQ: AYTU), a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology.  Prior to forming Aytu, Mr. Disbrow was the Chief Operating Officer of Ampio Pharmaceuticals ("Ampio", a NASDAQ traded company) and led the Luoxis Diagnostics subsidiary "Luoxis").

  • ACCESSWIRE9 months ago

    Emerging Developments: New Research on OptimizeRx and Zynex - A Look Ahead into 2018

    NEW YORK, NY / ACCESSWIRE / March 5 , 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of OptimizeRx Corp. (OTCQB: OPRX) and Zynex Inc. (OTCQB: ZYXI), including ...

  • Zynex Announces 2017 Fourth Quarter Earnings
    PR Newswire9 months ago

    Zynex Announces 2017 Fourth Quarter Earnings

    - Revenue grew 178% year over year to $8.1 million - Net income of $3.3 million increased 1,482% year over year; EPS $0.10 - Adjusted EBITDA of $3.9 million increased 481% year over year - Sixth consecutive ...